Neuregenix siRhoA drug patent granted in USA, Europe, Australia, India & China
Neuregenix has identified, tested and patented a novel siRNA drug (siRhoA) with proven neuroprotective and neuroregenerative activity for the retinal neurons that get damaged in glaucoma (granted ‘Neuron Regeneration’ patent numbers: US7943755; EP1802755; CA2584921; CN101084309; JP4704435; AU324236).
The innovation that our siRhoA drug represents, and its USP, is its multi-modal action, since it not only reduces the raised intra-ocular pressure that occurs in glaucoma, but also protects retinal neurons from further damage and enhances their regeneration, making it suitable for both early and late stage disease.